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Abstract 
BACKGROUND 
STN-DBS is well established to improve motor symptoms and quality of life in 
patients with PD. While non-motor symptoms are crucial for quality of life in these 
patients, only neuropsychiatric and neuropsychological symptoms have been 
systematically studied in a longitudinal design thus far. However, these are only a part 
of the spectrum of non-motor symptoms in PD. We hypothesized that STN-DBS is 
associated with a beneficial effect on a range of non-motor symptoms. 
 
METHODS 
In this multicenter, open, prospective, international study we investigated non-motor 
effects of STN-DBS in “real-life” use. We evaluated Non-motor Symptom Scale, and 
Questionnaire, PD Questionnaire-8, Scales for Outcomes of PD motor examination 
and complications, and activities of daily living preoperatively and at 6 months 
follow-up in 60 consecutive patients (35 male, mean age: 61.64 ±7.84 years, mean 
disease duration: 10.45 ±4.22 years) undergoing STN-DBS.  
 
RESULTS 
All outcomes improved significantly at 6 months follow-up (PD Questionaire-8, 
p=0.006; activities of daily living, p=0.012; all others, p<0.001; Wilcoxon signed-
rank, respectively paired t-test; Bonferroni-correction). Post-hoc analyses of Non-
motor Symptom Scale domains showed a significant reduction of sleep/fatigue and 
miscellaneous domains (p≤0.001), perceptual problems/hallucinations (p=0.036), and 
urinary (p=0.018) scores. Effect sizes were “moderate” effect for Non-motor 
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Symptom Scale, and motor complications, “large” for motor examination, and 
“small” for other outcomes. 
 
CONCLUSIONS 
This study provides first evidence that bilateral STN-DBS improves non-motor 
burden in patients with PD and opens the door to a more balanced evaluation of DBS 
outcomes. Further randomized studies are needed to confirm these findings and 
compare DBS non-motor effects to other  therapies such as infusion based treatments 
of advanced PD. 
1 Introduction 
Subthalamic nucleus (STN) deep brain stimulation (DBS) is well established for the 
symptomatic treatment of Parkinson’s disease (PD) improving motor symptoms, 
activities of daily living (ADL), and quality of life (QoL) 1-3. Non-motor symptoms 
(NMS) play a crucial role for QoL in patients with PD 4, 5. Long-term effects of DBS 
on neuropsychological 6, 7 and neuropsychiatric symptoms 8, 9 have been studied. 
However, these symptoms contribute only to a part of NMS in patients with PD. 
Previously published studies on a wider range of NMS have methodological 
limitations due to a lack of objective clinician-based 10 or patient-based assessment 11 
and small cohort sizes of only 10 subjects 12, 13. 
In this study, we therefore investigated prospective data using validated non-motor 
clinician-based and self-assessment outcome measures collected on 6 months follow-
up (6MFU) of a multicenter advanced therapies registry trial. Datasets from this 
registry has been recently analysed to publish the EuroInf study comparing 
apomoprhine with intrajejunal levdoopa infusion. We hypothesized that STN-DBS is 
associated with a reduction of NMS burden in patients with PD. 
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Furthermore, to investigate the relationship between changes of NMS, motor and QoL 
outcomes from baseline, an exploratory aim of our study was to analyse their 
correlation. 
 
2 Methods 
2.1 Design 
This was a multicenter, open, prospective, European registry study (Cologne, London, 
and Manchester) of a subgroup of the “Non Motor Symptoms study group” of the 
“International Parkinson’s disease and Movement Disorders Society” with a 
longitudinal follow-up  (EuroInf study). The “Non Motor Symptoms study group” has 
previously published results of two other arms of the EuroInf study (subcutaneous 
apomorphine and intrajejunal levodopa infusion therapies) 14.  
For the third arm, centers were chosen on the basis of experience in using motor and 
non-motor scales as well as performing DBS surgery and therapy. 
2.2 Subjects 
All patients were diagnosed according to British Brain Bank criteria 15 and were 
screened for treatment with DBS in accordance with consensus criteria of the 
International Parkinson’s disease and Movement Disorders Society due to an 
insufficient medical control of motor symptoms. All patients responded to levodopa 
with >30% improvement of motor symptoms, assessed by Unified Parkinson’s 
Disease Rating Scale (UPDRS)-III. Preoperatively, neuropsychiatric and 
neuropsychological assessments of patients were performed by consultant 
psychiatrists and neuropsychologists. Exclusion criteria were clinically significant 
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psychiatric diseases and Minimal Mental State Examination scores < 25 points as an 
indicator of neuropsychological impairment. 
2.3 Ethical approval 
The study was approved by the local ethics committees (Master vote: 12–145, 
Cologne; United Kingdom: National Research Ethics Service South East London 
REC 3; 10/H0808/141; NIHR portfolio (UKCRN) number 10084) and carried out in 
accordance with the Declaration of Helsinki. 
2.4 Clinical assessment 
Motor symptoms and NMS were assessed preoperatively in clinical MedON state and 
postoperatively on 6MFU in clinical MedON/StimON before an adjustment of 
stimulation parameters thus reflecting a “real-life” state. As part of the EuroInf study, 
the same scales were collected as reported previously for other invasive symptomatic 
therapies of PD (apomorphine- and intrajejunal levodopa-infusion therapy) 14, 16, 17. 
(A) Motor impairment was assessed with the Short Parkinson’s Evaluation Scale / 
Scales for Outcomes in Parkinson’s disease (SPES/SCOPA) motor examination 
which has been shown to highly correlate with the MDS-UPDRS motor examination 
18. Motor complications and ADL were also assessed with the SPES/SCOPA scale 
which correlates with corresponding parts of the UPDRS scale 19. Additionally, for a 
subset of patients, we examined UPDRS directly. 
(B) Non-motor symptoms were examined with two tests: 
(1) We collected data of the Non-Motor Symptom Scale (NMSS), a clinician-
administered scale which tests for nine domains of NMS with 30 questions 20. These 
questions are assessed with weighted scores of symptom severity and frequency. 
Severity of symptoms are rated by a range of 0 (none) to 3 points (major source of 
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distress and disturbance for patients) and frequency is assessed by a range of 1 (<once 
per week) to 4 (daily or all the time) points. The theoretically possible maximum 
NMSS total score is 360, the minimum score 0.  
(2) Furthermore, we also collected data of the Non-Motor Symptoms Questionnaire 
(NMSQ), a patient-based self-assessment questionnaire with dichotomous answers for 
the presence of NMS 21 with a maximum NMSQ total score of 30 corresponding to 
the number of questions.  
(C) Patients’ QoL was investigated with the self-assessment rating scale Parkinson’s 
Disease Questionnaire (PDQ) -8 22. The PDQ-8 was designed as a shortened version 
of the PDQ-39, quantifies the frequency of eight aspects of daily living with impact 
on the QoL, and has previously been deployed for the assessment of patients with 
invasive symptomatic therapies of PD 14, 16, 17, including STN-DBS 23. PDQ data is 
provided as PDQ-8 Summary Index 24. 
(D) In addition, we recorded the therapeutic medical regimen and stimulation 
parameters. The levodopa equivalent daily dose (LEDD) was computed according to 
a method previously published by Tomlinson et al. 25 and the total electric energy 
delivered was estimated according to a method previously published by Koss et al. 26. 
2.3 Statistical analysis 
All outcome parameters were checked for normality distribution with the Shapiro-
Wilk test or, when necessary, Kolmogorov-Smirnov test with Lilliefors correction. 
For longitudinal analyses of these parameters we computed Wilcoxon signed-rank 
test, respectively Student’s paired t-test when criteria for parametric tests were 
fulfilled. We used the Bonferroni method to correct Type I errors for multiple 
comparisons. All values are stated as mean ±SD, when the aforementioned criteria 
were fulfilled, unless stated otherwise. 
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To investigate the size of DBS effects, in addition to the difference between baseline 
and follow-up scores, the relative change [(mean Testbaseline - mean Test6MFU)/ mean 
Testbaseline)] and the Cohen’s effect size 27 were calculated. Effect size values ≥0.80 
are considered “large effect”, 0.50-0.79 “moderate effect”, and 0.20-0.49 “small 
effect” 28. We used half a SD at baseline (½SD TestBaseline) in a method previously 
applied to QoL outcomes to detect treatment responders 28. The number needed to 
treat for an improvement ≥½SD TestBaseline was calculated for each outcome 29. Also, 
to evaluate changes of specific aspects of NMS, we used post-hoc analyses of NMSS 
domain scores with the above mentioned methods. 
Furthermore, to investigate the relationship between all outcome parameters, we 
computed Spearman’s rho, respectively Pearson’s correlation analyses when criteria 
were fulfilled, for changes of values from baseline. To examine the relative 
importance of specific NMSS domains for QoL, we also calculated correlations 
between all domains and PDQ-8 Summary Index. These relationships are also 
reported as changes from baseline. 
 
3 Results 
Here we present data of 60 consecutive patients (35 male) aged 61.64 years (±7.84) 
with long histories of PD (10.45 ±4.22 years) and moderate to high LEDD (1073.55 
±475.93) at baseline. The median Hoehn & Yahr score was 2.75 (interquartile range: 
2-3).  
The assumption of normal distribution was violated for PDQ-8 Summary Index 
(p=0.015), and SPES/SCOPA motor examination (p=0.019), ADL (p=0.006) and 
motor complications scores (p=0.006), but not for NMSS total score (p=0.066), and 
NMSQ total score (p=0.200). 
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Bilateral STN-DBS in patients with PD significantly improved all outcome 
parameters applied in this study (see table 1). In particular, DBS significantly reduced 
NMS in the clinician-based NMSS total score (p<0.001) as well as in the patient-
based NMSQ total score (p<0.001). Using NMSS total score as a main outcome 
parameter the statistical power was 0.88 (α=0.05; two-sided test). 
Post-hoc analyses of NMSS domains, also reported in table 1, showed a significant 
reduction of sleep/fatigue (p<0.001), perceptual problems/hallucinations (p=0.036), 
urinary symptoms (p=0.018), and miscellaneous domain (p=0.001) scores. An 
illustration of NMSS domain scores is included in figure 1. 
In the latter domain questions regarding excessive sweating (p<0.001) and change in 
the ability to smell and taste (p=0.001) were significant. Additionally, trends were 
observed for cardiovascular (p=0.096) and gastrointestinal (p=0.082) symptoms. 
Furthermore, PDQ-8 Summary Index (p=0.006), ADL (p=0.012), and motor 
outcomes (motor examination and complications, p<0.001 respectively) improved 
significantly. 
The magnitude of improvement is indicated in table 2. DBS had a moderate effect 
size on NMSS total score (0.50) and SPES/SCOPA motor complications (0.66), a 
large effect size on SPES/SCOPA motor examination (0.81), and a small effect size 
on NMSQ total score (0.48), PDQ-8 Summary Index (0.47), and SPES/SCOPA ADL 
(0.43). Mean of all stated outcome parameters was -29.50% (±7.16). The mean effects 
size of all stated outcome parameters was 0.57 (±0.14) resulting in a number neded to 
treat of 2.12 (±0.24). Around 47% of patients treated with DBS improved (≥½SD 
TestBaseline or more) their QoL and around 42% improved NMS as indicated by the 
number needed to treat values. 
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UPDRS-III and -IV were available for a subset of patients (n=42 and n=43) and 
improved significantly on 6MFU (see table e-1) with large effect size (0.90 and 0.91) 
resulting in a number needed to treat of 1.62 and 1.60, respectively (see table e-2). 
LEDD reduction was 43.22% from 1073.55 (±475.93) to 609.59 (±337.25) and 
reached statistical significance (Student’s paired t-test: p<0.001). Mean total electic 
energy delivered was 88.51µJ (±83.78) at 6MFU. There was no significant inter-
hemispheric difference as the median and inter-quartile range of the right STN were 
36.30µJ and 19.97-68.80µJ and of the left STN were 63.47µJ and 16.38-84.94µJ 
(Wilcoxon signed-rank test: p=0.904). 
To explore the relationship between changes of outcome parameters from baseline to 
6MFU we computed correlation analyses (table 3) which showed a significant 
relationship between the improvements of NMSS total score and PDQ-8 Summary 
Index (p=0.001) as well as NMSQ total score (p=0.026). Interestingly, however, the 
reduction of NMSS total score was not significantly correlated to SPES/SCOPA 
motor examination and complications or ADL scores. The correlation analyses on the 
aforementioned subset of patients for which UPDRS data was available showed a 
significant relationship between the improvements of NMSS total score with UPDRS-
IV (p=0.012), but not with UPDRS-III (table e-3). 
Further correlation analyses between PDQ-8 Summary Index and NMSS domains 
(table 4) indicated a significant relationship with sleep/fatigue (p=0.016), 
mood/cognition (p<0.001), and attention/memory (p=0.001). Noteworthy, there was 
no correlation between PDQ-8 Summary Index and improvements of urinary and the 
miscellaneous NMSS domains in our cohort, although these domains significantly 
improved from baseline. 
During the study period, no significant adverse effects were observed.  
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4 Discussion 
This multicenter open label European study provides evidence that bilateral STN-
DBS improves NMS burden in patients with PD as has been suggested from some 
single cente studies in small cohorts.. Also, in accordance to previous studies 
investigating changes from baseline to 6MFU, in our cohort STN-DBS significantly 
improved motor outcomes and QoL 1, 30. Studies investigating changes of motor 
examination from baseline MedON to 6MFU MedON/StimON report comparable 
results for motor examination improvement 31, 32. 
Incorporating good clinical practice we assessed NMS, QoL and motor symptoms 
using validated scales in a multicenter approach for the first time. Our main 
observations indicate that continuous bilateral subthalamic DBS significantly 
improves NMS, in particular its following aspects: 
- Sleep/fatigue: Our results of a significant improvement of this domain are in 
accordance with previous studies reporting subjective and objective improvements 
of sleep efficiency, quality, and architecture after continuous bilateral STN-DBS 
33, 34. 
- Urinary symptoms: Previous studies have reported immediate effects of STN-
DBS on bladder control 35, most likely mediated through a modulation of 
information transfer between the periaqueductal grey area and the cortex 36. To 
our knowledge this is the first report of long-term effects of STN-DBS on urinary 
symptoms. 
- Perceptual problems/hallucinations: Our results are in line with previous studies 
which have shown that DBS may lead to an improvement of hallucinations in 
patients with PD 37. Although no correlations were found between LEDD 
reduction and an improvement of this NMSS domain (data not shown), a possible 
mechanism seems to be an amelioration of these symptoms depending on a 
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reduction of LEDD below patient-specific individual thresholds. Further studies 
are needed to investigate the relationship between STN-DBS and LEDD effects 
on perceptual problems and hallucinations. 
- In the miscellaneous domain: We found beneficial effects on olfactory 
symptoms and excessive sweating. While previous studies have shown a 
beneficial immediate 38 and long-term effect 39 of STN-DBS on sweating probably 
due to a reduction of ON/OFF fluctuations, the effect on olfactory symptoms may 
seem more surprising. However, a longitudinal study investigating STN-DBS 
effects on olfaction showed a significant improvement of odor identification 
thresholds, but not detection thresholds, on 6 and 12MFU 40, possibly indicating 
an improvement of cognitive odor information processing. Our results support 
these previous findings suggesting that STN-DBS may have a beneficial effect on 
olfaction. 
Additionally trends were observed for a beneficial effect of STN-DBS on the 
following aspects of NMS: 
- Cardiovascular symptoms: Previous studies have shown an immediate 
improving effect of STN-DBS on orthostatic regulation 41. In a study on 
immediate effects of STN-DBS on a range of NMS the severity of “dizziness” 
improved in the StimON-state 38. To our knowledge no longitudinal data of this 
kind have been published. The trend of improvement of cardiovascular symptoms 
observed in our study could indicate long-term effects of STN-DBS on 
cardiovascular symptoms; however, further studies are needed. 
- Gastrointestinal symptoms: A study by Arai and co-workers provided evidence 
for a long-term improvement of gastrointestinal dysfunction after STN-DBS 42. 
The observed trend of improvement of gastrointestinal symptoms in our study 
may support the aforementioned findings. 
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Also, a meta-analysis by Stowe and colleagues has shown an improvement of a range 
of NMS, including hallucinations, cardiovascular, gastrointestinal, and sleep and 
fatigue symptoms associated with a reduction of LEDD 43. The observed 
improvements of aforementioned aspects of NMS may therefore also reflect an 
indirect response to an LEDD reduction. However, DBS and LEDD reduction may 
also simultaneously exert effects, synergistic or competing, on NMS. A separation of 
these two seems difficult in a “real-life study”. Here we merely present data of “net 
outcome” of STN-DBS and LEDD change following DBS therapy initiation. The key 
findings of the current study is a beneficial overall effect of DBS initiation on QoL, 
motor symptoms and NMS. Further studies may help to further elucidate the interplay 
of effects and the weight of the individual components. 
Understanding this issue may also help to answer a closely connected question, as to 
how STN-DBS effects on NMS as a whole can be explained, when LEDD 
reduction is not responsible. One has to acknowledge that NMS is a 
conglomeration,and classification of NMS in PD suggests multifactorial origin 
)Todorova et al. Pract Neurol 2014. Todorova A, Jenner P, Ray Chaudhuri K. Non-motor 
Parkinson’s: integral to motor parkinson’s, yet often neglected. Practical Neurology.2014  
doi:10.1136/practneurol-2013-000741 
). Most importantly 2 key aspects of NMS include dopaminergic versus non 
dopaminergic symptoms as well as non motor fluctuations. From a pathophysiological 
point of view DBS of the STN may help some NMS such as mood, aspects of sleep 
dysfunction and dysautonomia by modulating the dopaminergic pathways as well as 
by reducing motor fluctuations and thereby by default, attenuating non motor 
fluctuations. in theory, at least two ways of action of DBS seem possible here: 
Discuss non motor fluctuations as this is a key effect (Storch et al Neurology 2013) 
Firstly, a direct modulation of basal ganglia-thalamo-cortical loops has been discussed 
by which, e.g., autonomic centers of the thalamus, lateral frontal, and anterior 
cingulate cortex could be modulated thus leading to improvements of symptoms like 
sweating and bladder control 36, 39.  
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Secondly, a spread of electric current to regions in proximity of the STN, by which, 
e.g., the PPN (pedunculopontine nucleus) could be modulated thus, e.g., resulting in 
an improvement of sleep architecture 44. 
How about the roles of sensorimotor, limbic and associative STN and its frontal 
connections and electrode placement. 
An interesting finding of the current study is that the improvement of NMSS total 
score was significantly correlated with the improvements of QoL (PDQ-8 Summary 
Index) and motor complications (UPDRS-IV) while the correlation between PDQ-8 
Summary Index and motor examination (SCOPA/SPES motor examination and 
UPDRS-III) did not reach statistical significance. This confirms previous studies that 
NMSS total score may be a greater determinant of QoL than motor impairment 4. 
As a “real-life study” the current work has a number of weaknesses and as such 
recommendations cannot be made on the basis of this study As a registry study this 
was not a randomized or placebo-controlled study with sham stimulation. Patients 
were selected and recruited in a consecutive fashion as per clinical routine and 
underwent a standard protocol for DBS initiation in accordance to published 
international selection criteria for DBS as well as standard agreed follow-up plans. 
Patient support provided by DBS companies (e.g. an introductory training to patient 
programming and recharging devices) was not systematically assessed in this study, 
but support was available for all patients in participating study centers. However, the 
multicenter set-up of the study is likely to ameliorate the bias caused by a single 
center design and the reali life designs has strong external validity Furthermore, our 
study of non-motor effects of STN-DBS, as an invasive symptomatic therapeutic 
option, has one of the largest patient numbers for studies of this kind and it is unlikely 
that a sham controlled study of this nature can be performed both for logistic and 
financial reasons 
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However, using clustering and stratification methods in cohorts with further extended 
patient numbers may allow a characterization of treatment responses of specific NMS 
subtypes 45. The aim of this process is to tailor individual therapeutic approaches for 
patients with PD based on their profile of NMS and motor symptoms. 
To conclude, STN-DBS ameliorates NMS burden in a range of aspects of NMS. In 
our cohort around 40% of patients treated with DBS improved their NMS. Number 
needed to treat results were consistent with relative change and effect size results for 
all outcome parameters. Reports of these parameters are needed to better understand 
responses to different treatment strategies like, e.g., DBS, conventional pharmaco-
therapy, and subcutaneous apomorphine and intra-jejunal levodopa infusion therapies. 
Further studies on treatment responses of specific NMS subtypes to different 
treatment strategies may help to eventually provide a basis for individualized 
medicine for patients’ “real-life requirements”. 
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Table 1 - Significant improvement of all outcomes. 
  
Baseline Follow-Up 
p Mean SD Mean SD 
NMSS total score 65.05 39.03 45.35 25.88 <0.001 
NMSS domains   
Cardiovascular 1.60 2.26 1.02 1.70 0.096 
Sleep/fatigue * 17.37 10.18 9.78 7.53 <0.001 
Mood/cognition 6.98 11.77 5.93 11.41 0.585 
Perceptual problems / 
hallucinations * 1.73 3.59 0.90 2.67 0.036 
Attention/memory 5.37 6.70 4.45 5.29 0.223 
Gastrointestinal 6.95 7.89 5.33 5.81 0.082 
Urinary * 10.73 9.81 7.83 7.55 0.018 
Sexual function 3.00 5.09 2.73 5.33 0.637 
Miscellaneous * 11.32 9.85 7.37 5.76 0.001 
NMSQ total score 10.76 4.90 8.42 4.35 <0.001 
PDQ-8 Summary 
Index 33.23 17.96 24.74 16.00 0.006 
SPES/SCOPA   
motor examination 14.32 5.53 9.83 5.11 <0.001 
ADL 7.57 5.87 5.87 2.91 0.001 
motor complications 4.96 3.20 2.85 2.62 <0.001 
* Post-hoc analyses of NMSS domains showed a significant improvement of these 
domains. 
 
  
Table 2 – Relative change, effect size and number needed to treat 
  
Relative change 
(%) Effect size 
Number needed 
to treat 
NMSS total score * -30.28 0.50 2.4 
NMSS domains   
Cardiovascular -36.46 0.26 4.29 
Sleep/fatigue * -43.67 0.74 1.94 
Mood/cognition -15.04 0.09 6.00 
Perceptual problems / 
hallucinations -48.08 0.23 7.50 
Attention/memory -17.08 0.14 4.62 
Gastrointestinal -23.26 0.21 3.53 
Urinary -27.02 0.30 3.34 
Sexual function -8.89 0.05 7.5 
Miscellaneous -34.9 0.40 2.61 
NMSQ total score -21.73 0.48 2.11 
PDQ-8 Summary 
Index -25.55 0.47 2.15 
SPES/SCOPA   
motor examination ** -31.00 0.81 1.82 
ADL -22.49 0.43 2.35 
motor complications * -42.54 0.66 1.87 
*  „Moderate“ effect size 
** „Strong“ effects size 
 
  
 
Table 3 – Spearman’s rank correlations between outcomes 
  
NMSS 
total 
score 
NMSQ 
total 
score 
PDQ-8 
Summary 
Index 
SPES / 
SCOPA 
motor 
examination 
SPES / 
SCOPA 
ADL 
NMSQ total 
score 
Correlation 
.290*     
Sig. (2-
tailed) 
.026     
N 59     
PDQ-8 
Summary 
Index 
Correlation .428** .371**    
Sig. (2-
tailed) 
.001 .004    
N 60 59    
SPES / 
SCOPA motor 
examination 
Correlation .174 .127 .293*   
Sig. (2-
tailed) 
.184 .339 .023   
N 60 59 60   
SPES / 
SCOPA ADL 
Correlation .253 .000 .398** .311*  
Sig. (2-
tailed) 
.065 1.000 .003 .022  
N 54 53 54 54  
SPES / 
SCOPA motor 
complications 
Correlation .201 .052 -.022 -.099 .168 
Sig. (2-
tailed) 
.144 .714 .874 .477 .224 
N 54 53 54 54 54 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
There were no missing data for NMSS total score, PDQ-8 Summary Index, and 
SPES/SCOPA motor examination. Missing data for SPES/SCOPA ADL and motor 
complications were acceptable and for NMSQ total score negligible. 
 
   
Table 4 – Correlations between PDQ-8 Summary Index and NMSS domains 
  
Cardio-
vascular 
Sleep / 
fatigue 
Mood / 
cognition 
Perceptual 
problems / 
halluci-
nations 
Attention / 
memory 
Gastro-
intestinal Urinary 
Sexual 
function 
Miscel-
laneous 
PDQ-8 
Summary 
Index 
Correlation .129 .311* ,496** .199 ,410** .127 .138 -.109 .180 
Sig. (2-tailed) .327 .016 .000 .128 .001 .333 .292 .406 .168 
N 60 60 60 60 60 60 60 60 60 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
There were no missing data for PDQ-8 Summary Index and NMSS domains. 
   
Legend to figure 1 
(a) Box plots and (b) radar chart of NMSS domains. Star marks significantly 
improved domains. (B) Domain scores normalized to baseline values per subject. 
Blue: baseline, copper: 6MFU. Bigger copper area reflects NMSS domain 
improvement (computation: 2 - 6MFU/baseline). 
